The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Markets Update: Investor Sentiment Tilts Marginally Bullish and Pro-Cyclical
Retirement Plans’ Rocky 2020…and Where Investors Go from Here
Markets Update: Investors Assess How and When to Position Portfolios for a Post-Vaccine Economy
Innovation in the Industrials Sector
The Battle for Our Screens, Part 4: The Moving Pieces of Tech Policy
Markets Update: How Emerging-Market Economies are Navigating a Recovery
The Battle for Our Screens, Part 3: Social Media in the Social Distancing Age
The Battle for Our Screens, Part 2: The Future of Work
The Battle for Our Screens, Part 1: The Race to Entertain Us
Markets Update: September Turbulence
Pandemic Perspectives: Insights from Our First Virtual Intern Class
Markets Update: European Leveraged Capital Markets
Exploring the Founder Journey with Launch With GS CEOs
Markets Update: Subdued Mood as S&P 500 Hits Record Highs
The Latest Outlook for U.S. Equities
Markets Update: U.S. Election in Focus
Why Diversity Drives Better Investment Performance
Markets Update: SPACs
How Companies Are Meeting Their Financing Needs
Markets Update: Balanced Bear Repair
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money